Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
SCOTTS MIRACLE-GRO CO (SMG) reported revenue of $3.41B and net income of $145.20M for the fiscal year ended 2025-09-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from SCOTTS MIRACLE-GRO CO’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Agricultural Chemicals.
Income
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.41B | $3.55B | $3.55B | $3.92B | $4.92B | $4.13B | $3.16B | $2.66B | $2.64B | $2.51B |
| Cost of revenue | $2.35B | Unavailable | Unavailable | Unavailable | $3.43B | $2.77B | $2.13B | $1.78B | $1.67B | $1.60B |
| Gross profit | $1.04B | Unavailable | Unavailable | Unavailable | $1.47B | $1.35B | $1.02B | $864.60M | $972.60M | $900.30M |
| Operating income | $358.60M | $208.80M | -$174.40M | -$434.00M | $723.00M | $585.20M | $409.60M | $198.90M | $433.40M | $447.60M |
| Net income | $145.20M | -$34.90M | -$380.10M | -$437.50M | $512.50M | $387.40M | $460.70M | $63.70M | $218.30M | $315.30M |
| Research & development | $34.80M | $34.60M | $35.70M | $45.30M | $45.40M | $39.70M | $39.60M | $42.50M | $39.90M | $36.00M |
| Weighted-average diluted shares | shares 58.70M | shares 56.80M | shares 56.00M | shares 55.50M | shares 57.20M | shares 56.90M | shares 56.30M | shares 57.10M | shares 60.20M | shares 62.00M |
| Pretax income | $221.70M | -$23.60M | -$453.30M | -$558.10M | $677.10M | $510.60M | $581.60M | $115.70M | $314.90M | $383.70M |
| Income tax expense | $76.50M | $11.30M | -$73.20M | -$120.60M | $159.80M | $123.70M | $144.90M | -$11.90M | $116.60M | $137.60M |
| Diluted EPS | $2.47 | $-0.61 | $-6.79 | $-7.88 | $8.96 | $6.81 | $8.18 | $1.12 | $3.63 | $5.09 |
| Selling, general & administrative | $603.40M | $559.00M | $551.30M | $613.00M | $743.50M | $757.80M | $601.30M | $540.10M | $550.90M | $518.00M |
| General & administrative | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Selling & marketing | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Balance
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $32.80M | $71.60M | $31.90M | $86.80M | $244.10M | $16.60M | $18.80M | $33.90M | $120.50M | $28.60M |
| Total assets | $2.74B | $2.87B | $3.41B | $4.30B | $4.80B | $3.38B | $3.03B | $3.05B | $2.75B | $2.76B |
| Current assets | $940.30M | $980.40M | $1.40B | $1.98B | $2.02B | $1.22B | $1.04B | $885.70M | $881.70M | $1.03B |
| Total liabilities | $3.10B | $3.26B | $3.68B | $4.15B | $3.79B | $2.68B | $2.31B | $2.69B | $2.09B | $2.02B |
| Current liabilities | $739.70M | $750.30M | $773.70M | $963.90M | $1.14B | $950.40M | $620.50M | $612.70M | $544.50M | $707.10M |
| Total equity incl. NCI | -$357.50M | -$390.60M | -$267.30M | $147.70M | $1.01B | $702.90M | $723.20M | $359.60M | $661.70M | $734.30M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $542.70M | $587.50M | $880.30M | $1.34B | $1.13B | $621.90M | $540.30M | $481.40M | $407.50M | $394.70M |
| Accounts receivable | $160.80M | $176.80M | $304.20M | $299.00M | $483.40M | $474.80M | $223.90M | $226.00M | $197.70M | $127.00M |
| Goodwill | $243.90M | $243.90M | $243.90M | $254.00M | $605.20M | $544.10M | $538.70M | $543.00M | $441.60M | $371.90M |
| Long-term debt | $2.05B | $2.17B | $2.56B | $2.83B | $2.24B | $1.46B | $1.52B | $1.88B | $1.26B | $1.03B |
| Accounts payable | $221.40M | $254.70M | $271.20M | $422.60M | $609.40M | $391.00M | $214.20M | $150.50M | $153.10M | $131.20M |
Cash flow
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $371.30M | $667.50M | $531.00M | -$129.00M | $271.50M | $558.00M | $226.80M | $342.50M | $363.20M | $244.00M |
| Capital expenditures | $97.40M | $84.00M | $92.80M | $113.50M | $106.90M | $62.70M | $42.40M | $68.20M | $69.60M | $58.30M |
| Investing cash flow | -$112.10M | -$100.40M | -$65.70M | -$283.20M | -$538.60M | $46.90M | $255.20M | -$580.70M | $22.40M | -$134.40M |
| Financing cash flow | -$294.00M | -$527.90M | -$520.10M | $255.30M | $494.00M | -$607.10M | -$496.50M | $151.20M | -$316.80M | -$128.80M |
| Net change in cash | -$35.00M | $39.70M | -$54.90M | -$157.30M | $227.50M | -$2.20M | -$15.10M | -$86.60M | $70.40M | -$21.30M |
| Stock-based compensation | $69.00M | $80.40M | $68.90M | $34.30M | $40.60M | $57.90M | $38.40M | $40.40M | $25.20M | $15.60M |
| Common dividends paid | $154.30M | $151.30M | $149.10M | $166.20M | $143.00M | $411.20M | $124.50M | $120.00M | $120.30M | $116.60M |
| Common share repurchases | $18.40M | $5.10M | $9.30M | $257.90M | $129.30M | $53.20M | $3.10M | $327.70M | $255.20M | $137.40M |
| Depreciation & amortization | Unavailable | $80.60M | $92.50M | $105.20M | $93.80M | $94.70M | $89.30M | $83.40M | $73.80M | $62.30M |
Derived
| Metric | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 | 2018-09-30 | 2017-09-30 | 2016-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | $273.90M | $583.50M | $438.20M | -$242.50M | $164.60M | $495.30M | $184.40M | $274.30M | $293.60M | $185.70M |
| Gross margin | 30.6% | 23.9% | 18.5% | 22.2% | 29.8% | 32.6% | 32.3% | 32.5% | 36.8% | 35.9% |
| Operating margin | 10.5% | 5.9% | -4.9% | -11.1% | 14.7% | 14.2% | 13.0% | 7.5% | 16.4% | 17.9% |
| FCF margin | 8.0% | 16.4% | 12.3% | -6.2% | 3.3% | 12.0% | 5.8% | 10.3% | 11.1% | 7.4% |
| SBC / revenue | 2.0% | 2.3% | 1.9% | 0.9% | 0.8% | 1.4% | 1.2% | 1.5% | 1.0% | 0.6% |
| Current ratio | 1.27x | 1.31x | 1.81x | 2.06x | 1.77x | 1.28x | 1.68x | 1.45x | 1.62x | 1.46x |
| Revenue YoY growth | -3.9% | 0.0% | -9.5% | -20.3% | 19.2% | 30.9% | 18.5% | 0.8% | 5.4% | Unavailable |
| Net margin | 4.3% | -1.0% | -10.7% | -11.1% | 10.4% | 9.4% | 14.6% | 2.4% | 8.3% | 12.6% |
| R&D / revenue | 1.0% | 1.0% | 1.0% | 1.2% | 0.9% | 1.0% | 1.3% | 1.6% | 1.5% | 1.4% |
| CapEx / revenue | 2.9% | 2.4% | 2.6% | 2.9% | 2.2% | 1.5% | 1.3% | 2.6% | 2.6% | 2.3% |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | 34.5% | Unavailable | Unavailable | Unavailable | 23.6% | 24.2% | 24.9% | -10.3% | 37.0% | 35.9% |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open SMG in the interactive workspace to inspect any figure back to its filing.
Source filings
Reconciliation checks needing review
3 periods on this page do not reconcile under this site’s normalization. Read that as a limitation here before an observation about the company: the figures are the filer’s own, the filings linked above are authoritative, and a difference usually means the concepts this site selected do not match how this filer presents its statements. Nothing is adjusted to make a check pass.
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.
Withheld: cost revenue, gross profit could not be reconciled with the rest of this filer’s statement.